An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy
Jeffrey Sulpher(BC Cancer Agency), Susan Dent(Washington Hospital), Franco Dattilo(University of Ottawa), Shrey Mathur(University of Ottawa), Daniel J. Lenihan(Saint Francis Medical Center), Nadine Graham(University of Ottawa), Ellamae Stadnick(University of Ottawa), Christopher Johnson(University of Ottawa), Angeline Law(University of Ottawa), Michèle Turek(Ottawa Hospital)
Cited by 18
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767